Previous Article | Back To List | Next Article

Lifetime Management of Arthritis – The Value of MTX in Clinical Practice

Top-class speakers address various issues on methotrexate (MTX) therapy during all stages of life at medac GmbH EULAR satellite symposium in Rome, Italy

Chicago, IL, June 9, 2015

Medac GmbH has invited internationally highly distinguished experts for a satellite symposium at the EULAR 2015 in Rome. The overall topic of the symposium reflects how methotrexate, the gold standard in therapy of rheumatoid arthritis, can accompany patients through stages of life.

“We feel honoured to have Prof James O’Dell chairing our symposium at this year’s EULAR. His work with MTX and other DMARDs in the well-known triple therapy is a milestone in the treatment of RA,” said Dr Ulrich Kosciessa, Managing Director of medac GmbH. As the world-wide leader for subcutaneous methotrexate therapy, Medac has a long tradition in supporting autoimmune research and application focussing on methotrexate. Kosciessa added: “Other highlights of our top-class symposium will be the discussion of MTX in early therapy presented by Dr Suzanne Verstappen, UK, Dr Ivan Foeldvari, Germany, talking about juvenile idiopathic arthritis, as well as Dr Gerolamo Bianchi, Italy, presenting data on MTX therapy improvement in middle-aged patients.”

Objectives of the symposium

Rheumatoid arthritis may affect patients at all stages in life. Methotrexate has been the disease-modifying anti-rheumatic drug (DMARD) of first choice for most age groups. The speakers of the symposium will discuss enhancement strategies of methotrexate and the management of tolerance issues such as dose adjustments, correct application of folic acid and switching to subcutaneous use. Also, patient-related topics as pregnancy and alcohol dependency are going to be considered. Finally, therapy adherence as another important aspect for all patient groups will be illustrated by current study results.

Despite recent medicinal developments, methotrexate has remained the gold standard in rheumatoid arthritis therapy, being a well-tolerated drug, making therapy affordable, and convincing with versatile applications. Medac GmbH aims to contribute to the success story of methotrexate by providing the drug world-wide under the brand names Metoject®, Metex® and Rasuvo™. The broad range of 10 dosages includes intermediate doses in ready-to-use syringes and autoinjectors.

Also, medac GmbH would like to recommend the new, innovative online help and support tool RA Coach for rheumatoid arthritis patients and their relatives. The RA Coach wants to enhance the disease self-management skills of RA patients and offers e.g. useful information and guided exercises (

About Medac Pharma: Practicing a patient-first philosophy

Medac Pharma, Inc. is a privately held specialty pharmaceutical company focused on the development, in-licensing and commercialization of late-stage molecules. The company strives to bring new life to products and solve everyday patient challenges in autoimmune disease and cancer.

Medac Pharma is the wholly-owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years. For more information about medac GmbH, please visit

For complete prescribing information, including Boxed Warning, and information on Medac Pharma’s CORE Connections program, please visit

Media Contact:
Medac Pharma, Inc.
Zachary Adamerovich